Literature DB >> 26656653

Damaged goods?: an empirical cohort study of blood specimens collected 12 to 23 hours after birth in newborn screening in California.

Hao Tang1, Lisa Feuchtbaum1, Partha Neogi1, Thomson Ho1, Leslie Gaffney1, Robert J Currier1.   

Abstract

PURPOSE: The current Clinical and Laboratory Standards Institute standard recommends blood collection from 24 to 48 hours after birth for newborn genetic disorder screening. We used California population-level data to determine whether early specimens (collected from 12 to 23 hours) would also be considered satisfactory based on screening performance.
METHODS: Screening data from California Genetic Disease Screening Program were analyzed for false-negative and false-positive rates in four disease categories: metabolic disorders detectable by tandem mass spectrometry (MS/MS); congenital adrenal hyperplasia (CAH); congenital hypothyroidism (CH); and initial immune reactive trypsinogen (IRT) for cystic fibrosis (CF). We compared the rates between the early-collection group (12 to 23 hours) and the standard-collection group (24 to 48 hours).
RESULTS: No significant difference of false-negative rate was detected between the two collection-timing groups. Early specimens had a significantly higher false-positive rate for CH (0.10 vs. 0.01%) and IRT (1.85 vs. 1.54%) but a lower false-positive rate for MSMS metabolic disorders (0.11 vs. 0.18%) and CAH (0.10 vs. 0.14%).
CONCLUSION: Newborn specimens collected after 12 hours provided satisfactory screening performance. A policy allowing earlier collection could improve timeliness of reporting screening results.

Entities:  

Mesh:

Year:  2015        PMID: 26656653     DOI: 10.1038/gim.2015.154

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  24 in total

1.  Detection of TPN contamination of dried blood spots used in newborn and metabolic screening and its impact on quantitative measurement of amino acids.

Authors:  Donald H Chace; Víctor R De Jesús; Timothy H Lim; W Harry Hannon; Reese H Clark; Alan R Spitzer
Journal:  Clin Chim Acta       Date:  2011-04-14       Impact factor: 3.786

2.  Hospital stay for healthy term newborns.

Authors: 
Journal:  Pediatrics       Date:  2004-05       Impact factor: 7.124

3.  Reduced activity of 11β-hydroxylase accounts for elevated 17α-hydroxyprogesterone in preterms.

Authors:  Clemens Kamrath; Michaela F Hartmann; Claudia Boettcher; Stefan A Wudy
Journal:  J Pediatr       Date:  2014-05-23       Impact factor: 4.406

4.  Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms.

Authors:  R L Puckett; F Lorey; P Rinaldo; M H Lipson; D Matern; M E Sowa; S Levine; R Chang; R Y Wang; J E Abdenur
Journal:  Mol Genet Metab       Date:  2009-12-05       Impact factor: 4.797

5.  Thyroid screening for early discharged infants.

Authors:  J G Saslow; E M Post; C A Southard
Journal:  Pediatrics       Date:  1996-07       Impact factor: 7.124

6.  Newborn phenylketonuria (PKU) Guthrie (BIA) screening and early hospital discharge.

Authors:  W B Hanley; H Demshar; M A Preston; A Borczyk; W E Schoonheyt; J T Clarke; A Feigenbaum
Journal:  Early Hum Dev       Date:  1997-01-03       Impact factor: 2.079

7.  Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours.

Authors:  D H Chace; J E Sherwin; S L Hillman; F Lorey; G C Cunningham
Journal:  Clin Chem       Date:  1998-12       Impact factor: 8.327

8.  Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California.

Authors:  Lisa Prach; Ruth Koepke; Martin Kharrazi; Steven Keiles; Danieli B Salinas; Maria Carmen Reyes; Mark Pian; Harry Opsimos; Kimberly N Otsuka; Karen Ann Hardy; Carlos E Milla; Jacquelyn M Zirbes; Bradley Chipps; Susan O'Bra; Muhammad M Saeed; Reddivalam Sudhakar; Susan Lehto; Dennis Nielson; Gregory F Shay; Mary Seastrand; Sanjay Jhawar; Bruce Nickerson; Christopher Landon; Ann Thompson; Eliezer Nussbaum; Terry Chin; Henry Wojtczak
Journal:  J Mol Diagn       Date:  2013-06-28       Impact factor: 5.568

9.  Newborn early discharge revisited: are California newborns receiving recommended postnatal services?

Authors:  Alison A Galbraith; Susan A Egerter; Kristen S Marchi; Gilberto Chavez; Paula A Braveman
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

10.  Postanalytical tools improve performance of newborn screening by tandem mass spectrometry.

Authors:  Patricia L Hall; Gregg Marquardt; David M S McHugh; Robert J Currier; Hao Tang; Stephanie D Stoway; Piero Rinaldo
Journal:  Genet Med       Date:  2014-05-29       Impact factor: 8.822

View more
  6 in total

Review 1.  Sequencing-based diagnostics for pediatric genetic diseases: progress and potential.

Authors:  Ahmad N Abou Tayoun; Bryan Krock; Nancy B Spinner
Journal:  Expert Rev Mol Diagn       Date:  2016-08-17       Impact factor: 5.225

2.  Newborn testing and screening by whole-genome sequencing.

Authors:  Stephen F Kingsmore
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

3.  Targeted next generation sequencing for newborn screening of Menkes disease.

Authors:  Richard B Parad; Stephen G Kaler; Evan Mauceli; Tanya Sokolsky; Ling Yi; Arindam Bhattacharjee
Journal:  Mol Genet Metab Rep       Date:  2020-07-21

4.  Timing of Newborn Blood Collection Alters Metabolic Disease Screening Performance.

Authors:  Gang Peng; Yishuo Tang; Tina M Cowan; Hongyu Zhao; Curt Scharfe
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

5.  dbRUSP: An Interactive Database to Investigate Inborn Metabolic Differences for Improved Genetic Disease Screening.

Authors:  Gang Peng; Yunxuan Zhang; Hongyu Zhao; Curt Scharfe
Journal:  Int J Neonatal Screen       Date:  2022-08-29

6.  The role of exome sequencing in newborn screening for inborn errors of metabolism.

Authors:  Jennifer M Puck; Steven E Brenner; Aashish N Adhikari; Renata C Gallagher; Yaqiong Wang; Robert J Currier; George Amatuni; Laia Bassaganyas; Flavia Chen; Kunal Kundu; Mark Kvale; Sean D Mooney; Robert L Nussbaum; Savanna S Randi; Jeremy Sanford; Joseph T Shieh; Rajgopal Srinivasan; Uma Sunderam; Hao Tang; Dedeepya Vaka; Yangyun Zou; Barbara A Koenig; Pui-Yan Kwok; Neil Risch
Journal:  Nat Med       Date:  2020-08-10       Impact factor: 53.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.